porting diabetes camps and it is one of the many ways we can help meet the everyday needs of families and children with type 1 diabetes."
Freeman's 2012 summer diabetes camp tour begins June 20 in Caribou, Maine, and runs through August 8. For more information about his work with Lilly Diabetes or for information about other Lilly Diabetes support programs, please visit www.lillydiabetes.com.
For information about diabetes camps in your area, visit www.diabetescamps.org.
Camp Adventure, Caribou, Maine–June 20
Camp Hopewell, Oxford, Miss. –June 27
Camp Sugar Falls, Antioch, Tenn.–June 28
Camp Hope, Casper, Wyo.–June 29
Camp Aspire, Rush, N.Y.–July 11
Gales Creek Camp, Forest Grove, Ore. –July 17
Camp Victory, Anacoco, La.–July 18
Triangle D Camp, Ingleside, Ill.–July 24
Camp Needles in the Pine, Blounts Creek, N.C.–July 25
Camp Kudzu, Atlanta, Ga.–August 8
About Lilly Diabetes
Lilly has been a global leader in diabetes care since 1923, when we introduced the world's first commercial insulin. Today we work to meet the diverse needs of people with diabetes through research and collaboration, a broad and growing product portfolio and a continued commitment to providing real solutions–from medicines to support programs and more–to make lives better. For more information, visit www.lillydiabetes.com.
About Eli Lilly and Company
Eli Lilly and Company (NYSE: LLY), a leading innovation-driven company, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations Page: 1 2 3 4 Related medicine technology :1
. DiversityInc Names Lilly a Top Company for Diversity2
. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics3
. Lilly Sets Date for Lilly Diabetes Pipeline Update to the Investment Community4
. Lilly Applauds Law Enforcement Officials for their Successful Investigation and Recovery of Pharmaceuticals Stolen from Connecticut Distribution Center5
. Lilly Oncology To Disclose New Pipeline Data At ASCO 20126
. Lilly Diabetes Presents Phase II Blood Pressure and Heart Rate Data on Investigational GLP-1 Analog Candidate, Dulaglutide, in Patients with Type 2 Diabetes at the 27th American Society of Hypertension Scientific Meeting7
. Lilly and Incytes Oral JAK1 and JAK2 Inhibitor, Baricitinib, Showed Positive Results in Phase IIb Study in Patients with Active Rheumatoid Arthritis8
. Lilly and Boehringer Ingelheim Present Data at the 72nd American Diabetes Association Scientific Sessions® from Phase II Studies Comparing Investigational Novel Basal Insulin to Insulin Glargine9
. Lilly Expands Strategic Partnership with Chinese Manufacturer Novast to Serve Chinese Patients with High-Quality Branded Generic Medicines10
. Lexicon Receives Funding for Phase 2 Clinical Trial of LX4211 in Type 1 Diabetes11
. Islet Sciences Announces Exclusive License Agreement with Yale University to Commercialize an Early Beta Cell Destruction and Diabetes Diagnostic